Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICHD spermicide trial receives FDA advisory committee endorsement.

This article was originally published in The Tan Sheet

Executive Summary

NICHD SPERMICIDE TRIAL ENDORSED BY FDA ADVISORY COMMITTEES at a Nov. 22 joint meeting of FDA's Nonprescription Drugs, Reproductive Health Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees in Gaithersburg, Md. The joint committee overwhelmingly agreed that more efficacy data is needed for marketed OTC vaginal spermicides and lauded the National Institute of Child Health & Human Development's proposed four-year, 1,200-subject study of several marketed nonoxynol-9-containing vaginal spermicides as a source of much-needed information on efficacy in pregnancy prevention.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel